Jazz Pharmaceuticals Raises 2026 Revenue Outlook

Jazz Pharmaceuticals raised its 2026 revenue outlook to $4.775 billion–$4.85 billion. Third-quarter sales grew 12% year over year for Xywav and 32% for Zepzelca, partly offset by declines in Epidiolex and Xyrem sales. The company maintained gross-margin guidance of 89%–90% and expects a GAAP tax rate of 20%–30%.